Skip to main content
Neurology logoLink to Neurology
. 2013 Jul 2;81(1):e3. doi: 10.1212/WNL.0b013e318297eef5

Teaching NeuroImages: Diagnostic utility of FDG-PET in neurolymphomatosis

Michel Toledano 1,, Mustaqeem A Siddiqui 1, Carrie A Thompson 1, Ivan Garza 1, Sean J Pittock 1
PMCID: PMC3770198  PMID: 23817522

Abstract

A 70-year-old woman with a history of non-Hodgkin lymphoma presented with left-sided facial pain. MRI of the face, orbit, and neck was negative (figure). A week later, she developed hypesthesia in a V3 distribution. Repeat MRI was again nondiagnostic but FDG-PET showed increased uptake along the left V3 branch of the trigeminal nerve, as well as in the parotid gland. Biopsy of the left parotid confirmed recurrent lymphoma.


A 70-year-old woman with a history of non-Hodgkin lymphoma presented with left-sided facial pain. MRI of the face, orbit, and neck was negative (figure). A week later, she developed hypesthesia in a V3 distribution. Repeat MRI was again nondiagnostic but fluorodeoxyglucose (FDG)-PET showed increased uptake along the left V3 branch of the trigeminal nerve, as well as in the parotid gland. Biopsy of the left parotid confirmed recurrent lymphoma.

Figure. Face, orbit, and neck imaging.

Figure

Axial MRI T1 gadolinium images without any contrast enhancement at the level of the trigeminal nerve (A) or parotid gland (D). PET reveals a focus of intense fluorodeoxyglucose (FDG) avidity extending through the foramen ovale along the course of the left V3 branch of the trigeminal nerve in both axial (B) and coronal (C) cuts, consistent with perineural spread of disease. Axial (E) and coronal (F) cuts show increased FDG activity in the left parotid gland.

Neurolymphomatosis is a rare manifestation of hematologic disease and diagnosis is often delayed.1 Our case illustrates the utility of FDG-PET in establishing the diagnosis of neurolymphomatosis when suspicion is high but MRI is unrevealing.2

Supplementary Material

Teaching Slides

Footnotes

Download teaching slides: www.neurology.org

AUTHOR CONTRIBUTIONS

Drs. Toledano, Garza, and Pittock made substantive contributions to the design of the study and drafting of the manuscript. Drs. Siddiqui and Thompson made substantive contributions to the revision of the manuscript.

STUDY FUNDING

No targeted funding reported.

DISCLOSURE

The authors report no disclosures relevant to the manuscript. Go to Neurology.org for full disclosures.

REFERENCES

  • 1.Grisariu S, Avni B, Batchelor TT, et al. Neurolymphomatosis: an International Primary CNS lymphoma Collaborative Group report. Blood 2010;115:5005–5011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Salm LP, Van der Hiel B, Stokkel MP. Increasing importance of 18F-FDG PET in the diagnosis of neurolymphomatosis. Nucl Med Commun 2012;33:907–916 [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Teaching Slides

Articles from Neurology are provided here courtesy of American Academy of Neurology

RESOURCES